SRX 0.00% $33.55 sirtex medical limited

SRX is a buy (imo)Chartists?

  1. 25,374 Posts.
    lightbulb Created with Sketch. 3
    SRX is a buy , and it doesnt feel like 9/11...phew. a great day on the cards

    Picked up on Metastock 040702 (formula via Darryl Guppy)
    the chart rising against the XJO
    P&F confirms

    52-Week Range: 46-254
    ISIN: AU000000SRX1
    Current Bid: 195
    Current Ask: 198
    Total Class Issue: 19,607,006
    CHESS Eligibility: CHESS eligible
    Net Tangible Assets ($/share): $0.22
    Code: SRX Div. Payable Date: 20/03/2002
    Open: - Ex. Div. Date: -
    Day High: - Franked Pct: 0%
    Day Low: - Status: Normal
    Trades: 0 Earnings/Share: -5.18
    Volume: 0 Div. Rate/Share: 0
    Value: $0 P/E: -
    Market Cap (Undiluted): 38,233,662 Industry Sector: Healthcare & Biotechnology
    Previous Close: 195 Industry Group: Biotechnology

    From ASX

    Sirtex announces pleasing results from SIR-Spheres
    11:27, Monday, 20 May 2002

    Sydney - Monday - May 20: (RWE) - Sirtex Medical Ltd today
    announced it was "extremely pleased" with the results of a randomised
    clinical trial involving the use of SIR-Spheres in patients with
    advanced bowel cancer that had spread to the liver.
    The results were presented to the annual meeting of the American
    Society of Clinical Oncology in Orlando, Florida in May.
    About half of the 11,000 Australians diagnosed with bowel cancer
    each year will go onto develop liver cancer within five years.
    Spread of the cancer to the liver is the main method of spread
    of the disease and also the major cause of mortality in these patients.
    The clinical trial involved 21 patients and was designed to
    compare the response to treating patients with either chemotherapy alone
    using fluorouracil and leucovorin or the same chemotherapy but with the
    addition of a single administration of SIR-Spheres.
    Sirtex reports that no patient receiving chemotherapy alone
    responded as compared to 91 per cent of patients who also received the
    The company said the 'time-to-tumour-progression' - or the
    measure of how long the tumour in the liver could be stopped from
    growing - revealed further encouraging results.
    In patients treated with chemotherapy alone it is 4.7 months,
    compared to 15.6 months for patients receiving the SIR-Spheres.
    "Both the increased response rate and increased time to tumour
    progression that was observed for patients treated with SIR-Spheres were
    of high statistical significance," Sirtex said.
    Sirtex medical director Dr Bruce Gray said: "This small trial is
    an extraordinary demonstration of the effectiveness of treating patients
    with SIR-Spheres.
    "It would be hard to conceive of a better result from a single
    administration of an anti-cancer agent in this difficult to treat group
    of patients.
    "We are extremely pleased with the result, which adds to the
    mounting database on the effectiveness of this therapy.
    "Many oncologists who have seen this data were surprised at the
    results and are looking for a larger repeat study to confirm the
    results," Dr Gray said.
    Shares in Sirtex Medical were up 28c to $1.70 this morning.
    Copyright © 2002 RWE Australian Business News. All rights reserved.

    looking for trigger to enter SRX today>195-198<
    or lower on retrace
    stop at 182 (cbl3)
    2% cap loss
    trading to a plan lol

watchlist Created with Sketch. Add SRX (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.